Concizumab: A Breakthrough Prophylaxis for Hemophilia B and A with Inhibitors
The World Federation of Hemophilia (WFH) shared a breakthrough for hemophilia with inhibitors on X:
”While treatment options have advanced, people with hemophilia B and inhibitors still face major gaps. A new review explores concizumab, a subcutaneous prophylaxis option that could help close that gap and improve outcomes.”
Read the full article here.
Despite advancements in hemophilia treatment, people with hemophilia A or B (HA, HB) and inhibitors face significant unmet needs, particularly in prophylaxis.
While emicizumab addresses prophylaxis for HA with inhibitors, no such option existed for HB until the arrival of concizumab.
This novel, subcutaneous treatment—approved since 2023 in countries like Canada, Australia, Japan, and Switzerland—is the first prophylactic therapy for HB with inhibitors.
The drug also offers new hope for HA patients with persistent bleeds on emicizumab.
With a unique mechanism of action, convenient multi-dose pen delivery, and quick washout, concizumab is poised to improve quality of life and long-term outcomes in this historically underserved population.
Hemostasis Today, your daily update on the latest advancements in the field of Hemophilia.
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 21, 2025, 03:503 Questions With Abigail Ajanel Gomez – Touch Haematology Future Leader 2025
-
Oct 21, 2025, 01:57Mohamed Reda: Clotting Factors — The Key Players in Blood Coagulation
-
Oct 20, 2025, 13:23From Words to Action: David McIntosh Advocates for Investment in Lifesaving Maternal Care
-
Oct 20, 2025, 13:21Royal College of Physicians of Edinburgh: Haematology 2025 — Presentation, Prevention and Possibilities
-
Oct 21, 2025, 11:13Hanny Al Samkari's Commentary on Iron Deficiency Anemia in Inherited Bleeding Disorders
-
Oct 21, 2025, 11:08Wolfgang Miesbach on New Real-World Data for Haemophilia B Prophylaxis
-
Oct 21, 2025, 06:44Asmaa A About Pseudo Thrombocytopenia: Causes and How to Handle
-
Oct 21, 2025, 06:41Natural Anticoagulants in Focus․ Protein C and S
-
Oct 21, 2025, 05:54John Strouse on Hydroxyurea for Children with Sickle Cell Disease
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 21, 2025, 06:18Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 21, 2025, 11:11Nana Kwame Kwabi Boateng: Grateful For The Opportunity to Serve As A SEARCH Ambassador
-
Oct 21, 2025, 05:00Sheila Cristina Ouriques Martins Is Grateful to Be Among The Legends Who Changed The Reality of Stroke Worldwide
-
Oct 21, 2025, 01:47Cathy Bliem: Yesterday, I Made My 4th Plasma Donation of 2025...
-
Oct 20, 2025, 12:40Asfand Yar Cheema: Honored to be featured in Video Journal of Hematology and Hematological Oncology
-
Oct 20, 2025, 12:25Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment